Market Cap 33.50M
Revenue (ttm) 0.00
Net Income (ttm) -51.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,200
Avg Vol 169,320
Day's Range N/A - N/A
Shares Out 30.18M
Stochastic %K 57%
Beta -0.08
Analysts Hold
Price Target $1.67

Latest News on ANTX

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Feb 20, 2025, 7:00 AM EST - 3 months ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences


AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 16, 2024, 7:00 AM EDT - 10 months ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan


AN2 Therapeutics to pause lung disease study enrollment

Feb 12, 2024, 6:56 AM EST - 1 year ago

AN2 Therapeutics to pause lung disease study enrollment


AN2 Therapeutics to Present at Upcoming Investor Conferences

Nov 6, 2023, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Present at Upcoming Investor Conferences


AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 25, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference


AN2 Therapeutics: Boron Chemistry For Infectious Diseases

May 5, 2023, 1:55 PM EDT - 2 years ago

AN2 Therapeutics: Boron Chemistry For Infectious Diseases